Tiltan Pharma is an Israeli biopharmaceutical company, established in 2006, that developed a proprietary anti-angiogenic and immune modulatory platform technology, for the treatment of cancer. The platform technology was originally developed by Prof. Shmuel (Muli) Ben Sasson from the Hebrew University.
Tiltan's clinical-stage leading product TL-118, is an oral drug combination with anti-cancer, anti- angiogenic and immune modulatory properties. The novelty of TL-118 is re-purposing of four approved drugs, with known safety profiles, optimized as a combined anti-cancer therapy in a unique regimen (dose and scheduling). The TL-118 regimen consists of low-dose-high-frequency (metronomic) administration of an alkylating agent and 3 non-cytotoxic agents previously approved for human use, for non-oncological indications.
TL-118 was tested in numerous animal tumor models and in over 150 cancer patients. Currently, Tiltan is conducting a randomized, open label phase-IIb clinical trial in metastatic pancreatic cancer under an FDA approved IND. The trial is conducted in Israel and Eastern Europe. The trial is no longer recruiting patients.
Built by Badboy.co.il
© copyright 2015 Tiltan Pharma